year
mark
anniversari
landmark
paper
would
huge
impact
emerg
field
biotechnolog
paper
milstein
describ
protocol
immort
b
cell
fuse
myeloma
cell
result
fusion
product
combin
capac
origin
b
cell
plasma
cell
immort
myeloma
cell
clone
line
fusion
product
call
hybridoma
produc
rel
larg
amount
antibodi
call
monoclon
antibodi
impact
hybridoma
technolog
underestim
nowaday
monoclon
antibodi
found
applic
virtual
branch
life
scienc
therapeut
potenti
monoclon
antibodi
quickli
recogn
result
larg
number
lifesav
therapeut
prophylact
antibodi
current
produc
market
pharmaceut
industri
first
gener
antibodi
develop
clinic
applic
mous
monoclon
antibodi
myeloma
fusion
partner
b
cell
mous
origin
first
antibodi
approv
clinic
antibodi
human
compon
receptor
complex
approv
treatment
transplant
delet
cell
therebi
reduc
damag
effect
antigraft
reaction
clinic
util
turn
limit
immunogen
human
among
problem
mous
antibodi
therapeut
antibodi
chimer
antibodi
constant
domain
mous
immunoglobulin
replac
human
two
exampl
chimer
antibodi
rituximab
antibodi
antigen
use
therapi
malign
variou
diseas
infliximab
antibodi
tumor
necrosi
factor
tnf
use
inflammatori
diseas
crohn
diseas
rheumatoid
arthriti
advanc
antibodi
engin
result
techniqu
fulli
human
mous
antibodi
graft
complementar
determin
region
cdr
region
human
immunoglobulin
ig
g
framework
although
human
mous
antibodi
still
use
anim
human
ig
gene
use
grow
number
compani
rais
therapeut
antibodi
parallel
use
mice
human
ig
gene
technic
advanc
antibodi
human
technolog
develop
directli
gener
fulli
human
antibodi
phage
display
one
technolog
method
use
librari
bacteriophag
engin
display
antibodi
fragment
surfac
bacteriophag
screen
bind
target
protein
order
identifi
antibodi
fragment
interest
review
technolog
advantag
method
human
b
cell
use
make
ig
librari
repres
natur
occur
repertoir
howev
phage
display
antibodi
frequent
unstabl
artifici
pair
heavi
light
chain
current
three
antibodi
approv
clinic
use
amongst
antibodi
adalimumab
method
gener
fulli
human
antibodi
involv
pcr
direct
rna
sequenc
singl
plasma
cell
blast
latter
select
flow
cytometri
use
label
antigen
method
requir
prior
knowledg
antigen
substanti
frequenc
b
cell
sampl
immort
human
b
cell
provid
us
method
cope
difficulti
isol
rare
antibodi
provid
technolog
immort
b
cell
effici
includ
captur
complet
repertoir
gener
stabl
immort
b
cell
although
fusion
b
cell
myeloma
cell
method
choic
immort
mous
b
cell
sever
drawback
limit
applic
isol
rare
b
cell
first
effici
immort
rather
low
low
proport
total
mous
repertoir
captur
hybridoma
technolog
clone
often
instabl
secondli
wherea
technolog
work
well
mous
rat
b
cell
attempt
gener
hybridoma
human
b
cell
limit
success
caus
lack
good
fusion
partner
human
b
cell
recent
success
rate
improv
develop
better
fusion
partner
technic
advanc
use
electrofus
viru
ebv
transform
commonli
use
way
immort
human
b
cell
frequenc
transform
tradit
low
increas
consider
use
agonist
use
technolog
group
lanzavecchia
gener
number
broadli
react
highli
neutral
antibodi
varieti
pathogen
virus
clone
human
b
cell
also
obtain
expand
individu
cell
cytokin
like
interleukin
il
although
number
interest
monoclon
antibodi
gener
instanc
technolog
limit
b
cell
expand
transient
protocol
therefor
method
offer
limit
window
opportun
find
desir
clone
one
possibl
reason
limit
prolif
capac
b
cell
stimul
cytokin
activ
b
cell
differenti
plasma
cell
set
plasma
cell
termin
differenti
cell
unabl
prolifer
observ
group
forc
express
known
inhibit
termin
differenti
plasma
cell
activ
b
cell
enabl
cell
continu
prolifer
respons
cytokin
consist
hypothesi
review
give
overview
work
regul
b
cell
knowledg
led
develop
conveni
antibodi
discoveri
platform
applic
wide
rang
speci
b
cell
develop
select
germin
center
gc
structur
secondari
lymphoid
organ
aris
consequ
antigen
stimul
gc
consist
two
distinct
area
call
dark
dz
light
zone
lz
respect
gc
microenviron
contain
multipl
cell
type
provid
signal
includ
cytokin
chemokin
support
prolifer
migrat
differenti
b
cell
cytokin
support
differenti
gc
includ
activ
signal
transduc
activ
transcript
stat
particularli
b
cell
express
phosphoryl
found
lz
gc
human
tonsil
suggest
play
role
b
cell
human
like
involv
prolifer
human
b
cell
knockdown
use
rna
interfer
strongli
decreas
prolifer
b
cell
stimul
presenc
determin
exact
role
function
express
fusion
mutat
domain
estrogen
receptor
er
activ
b
cell
examin
respons
cell
follow
incub
tamoxifen
ht
observ
addit
ht
strongli
enhanc
prolif
respons
b
cell
interestingli
ectop
express
constitut
activ
form
result
vitro
prolifer
b
cell
cultur
cytokin
wherea
control
transduc
b
cell
prolifer
limit
period
time
result
contradict
studi
mous
model
demonstr
involv
earli
develop
matur
delet
b
cell
use
cre
flox
allel
result
diminish
antibodi
product
also
mous
b
cell
prolifer
normal
respons
igm
stimul
perhap
effect
mice
exclus
mediat
wherea
human
may
involv
process
well
continu
expans
human
b
cell
constitut
activ
like
mediat
control
target
forc
express
human
b
cell
also
result
sustain
prolifer
human
b
cell
respons
cytokin
effect
overexpress
activ
human
b
cell
howev
ident
notabl
continu
overexpress
activ
eventu
result
downregul
ig
gene
express
b
cell
marker
presum
epigenet
repress
cell
eventu
acquir
featur
hodgkin
lymphoma
cell
highli
express
gc
b
cell
studi
mous
demonstr
essenti
format
gc
function
support
prolifer
inhibit
differenti
prolifer
b
cell
plasma
cell
mice
human
also
allow
cytidin
deaminas
aid
somat
hyper
mutat
shm
class
switch
recombin
csr
involv
extens
dna
modif
counteract
dna
damag
respons
regul
aid
repress
microrna
plasma
cell
character
express
differ
set
transcript
factor
import
encod
essenti
plasma
cell
differenti
need
format
machineri
secret
larg
amount
antibodi
crossregul
protein
bind
locu
repress
express
therebi
inhibit
plasma
cell
differenti
ratio
therefor
one
determin
factor
whether
activ
b
cell
pois
becom
plasma
cell
memori
cell
type
find
forc
express
inhibit
plasma
cell
differenti
allow
sustain
prolifer
activ
b
cell
confirm
speci
includ
primat
rabbit
llama
mice
ex
vivo
isol
human
memori
b
cell
express
protein
therefor
unlik
need
mainten
memori
state
human
b
cell
line
upon
forc
express
activ
peripher
blood
b
cell
cultur
cytokin
cell
acquir
featur
gc
b
cell
specif
cell
show
similar
plasmablast
produc
immunoglobulin
also
express
receptor
bcr
cell
membran
transduc
peripher
memori
b
cell
express
cell
surfac
antigen
also
found
gc
b
cell
also
express
aid
enzym
mediat
two
import
process
gc
b
cell
shm
csr
aid
function
b
cell
clone
line
human
b
cell
show
mutat
igg
h
l
chain
monoclon
antibodi
accumul
time
intriguingli
howev
csr
occur
b
cell
indic
shm
csr
differenti
regul
csr
shm
use
differ
domain
aid
therefor
uncoupl
shm
gene
convers
shown
howev
mechan
underli
lack
csr
b
cell
undergo
shm
present
unknown
taken
togeth
seem
master
regul
confer
gc
phenotyp
function
peripher
blood
memori
b
cell
observ
patient
suffer
autosom
domin
syndrom
establish
critic
role
regul
matur
caus
mutat
result
express
domin
neg
reduc
function
patient
show
high
suscept
microbi
pathogen
due
defici
function
varieti
immun
cell
antibodi
product
strongli
affect
although
defici
impair
function
follicular
helper
cell
therebi
hamper
help
defici
function
also
intrins
affect
capac
b
cell
differenti
plasmablast
sever
cytokin
induc
activ
b
cell
includ
like
domin
induc
b
cell
patient
mutat
defici
antibodi
respons
moreov
strongli
induc
express
activ
naiv
memori
b
cell
result
plasma
cell
differenti
increas
antibodi
product
studi
effect
activ
absenc
cytokin
signal
follow
approach
express
fusion
mutat
domain
er
activ
b
cell
examin
respons
cell
follow
incub
ht
experi
reveal
activ
increas
express
similar
suggest
transcript
factor
control
howev
wherea
induc
induc
transient
induc
phosphoryl
direct
target
human
b
cell
like
regul
howev
sustain
eventu
b
cell
cultur
differenti
termin
plasma
cell
knowledg
obtain
studi
regul
human
matur
provid
us
conveni
method
immort
human
b
cell
genet
modif
rather
fusion
myeloma
cell
transform
forc
express
b
cell
gene
transfer
prevent
cell
differenti
plasma
cell
cultur
system
mous
fibroblast
cytokin
howev
pool
b
cell
express
expand
slowli
probabl
caus
fact
mani
cell
die
offset
cell
death
examin
whether
gene
fragment
encod
antiapoptot
molecul
would
prevent
cell
death
cell
inde
varieti
gene
encod
famili
member
result
strong
inhibit
death
cell
best
effect
observ
also
effect
data
shown
b
cell
expand
rapidli
respons
varieti
cytokin
includ
robust
prolifer
achiev
mention
previou
paragraph
cell
inhibit
differenti
plasma
cell
nonetheless
capabl
secret
signific
amount
antibodi
besid
differ
effect
prolifer
also
observ
differ
capac
induc
product
antibodi
induc
highest
antibodi
titer
like
contrast
activ
promot
secret
antibodi
combin
overexpress
cultur
system
provid
us
b
cell
sever
properti
enabl
isol
antibodi
fig
b
cell
clone
select
base
antibodi
secret
cultur
supernat
use
test
specif
antibodi
properti
eg
inhibit
viral
infect
cell
bind
cytotox
cytotox
use
direct
function
screen
approach
identifi
respiratori
syncyti
viru
rsv
antibodi
antibodi
parecho
viru
staphylococcu
antibodi
antibodi
secret
maintain
stabl
cultur
allow
multipl
round
cellular
clone
abil
perform
multipl
screen
assay
select
process
high
level
bcr
express
detect
transduc
cell
compar
normal
b
cell
fluoresc
tag
antigen
bind
specif
bcr
enabl
isol
specif
b
cell
polyclon
pool
use
flow
cytomet
label
antigen
use
includ
small
peptid
monomer
protein
protein
complex
also
cell
wall
fraction
particl
addit
round
select
done
use
differ
protein
select
b
cell
recogn
common
conserv
epitop
antigen
success
appli
sort
isol
tetanu
toxoid
antibodi
broadli
neutral
influenza
antibodi
rsv
infect
main
caus
lower
respiratori
tract
diseas
develop
world
rsv
main
viral
etiolog
sever
pneumonia
bronchiol
contribut
consider
burden
health
servic
especi
prematur
neonat
children
bronchopulmonari
dysplasia
congenit
heart
diseas
risk
patholog
consequ
rsv
infect
nair
et
al
estim
rsv
account
million
hospit
death
per
year
mainli
occur
develop
countri
current
vaccin
confer
protect
rsv
human
monoclon
antibodi
specif
rsv
f
protein
palivizumab
prophylact
administ
children
risk
earli
protect
rsv
import
lower
respiratori
tract
infect
earli
life
especi
infant
associ
wheez
asthma
infanc
later
life
rsv
also
viral
etiolog
may
caus
enhanc
airway
sensit
could
result
airway
asthma
prophylact
treatment
children
may
therefor
result
signific
reduct
wheez
day
first
year
life
develop
asthma
later
life
requir
palivizumab
make
medicin
less
use
treatment
larg
group
newborn
treatment
possibl
young
infant
weigh
less
kg
therefor
search
medicin
potent
neutral
antibodi
continu
reason
human
expos
rsv
would
superior
sourc
neutral
antibodi
compar
mice
use
immort
technolog
set
identifi
antibodi
better
equal
potent
palivizumab
order
screen
directli
neutral
activ
develop
sensit
neutral
assay
use
detect
method
distinguish
quantifi
infect
cell
use
memori
igg
b
cell
deriv
peripher
blood
healthi
individu
includ
daycar
provid
frequent
expos
respiratori
virus
isol
seri
clone
produc
rsv
antibodi
antibodi
neutral
rsv
b
strain
potenc
greater
palivizumab
demonstr
antibodi
specif
f
structur
determin
present
inactiv
viru
viral
lysat
reason
unravel
mclellan
et
al
determin
exact
structur
f
protein
crystallographi
becam
clear
structur
target
antibodi
prefus
f
trimer
epitop
f
recogn
annot
domain
epitop
locat
apex
rsv
f
glycoprotein
therebi
lock
f
protein
prefus
state
bind
anoth
quaternari
epitop
f
protom
make
extrem
specif
bind
prefus
f
trimer
vitro
antibodi
neutral
broad
select
subgroup
subgroup
b
rsv
clinic
isol
advantag
antibodi
recogn
f
protein
nativ
conform
viru
particl
infect
cell
recogn
free
monomer
protein
probabl
abundantli
present
infect
may
serv
sink
antibodi
like
palivizumab
recogn
postfus
f
structur
antibodi
also
potent
vivo
activ
cotton
rat
altogeth
antibodi
like
test
vivo
prematur
infant
name
may
use
prevent
rsv
infect
first
month
life
given
prophylact
immedi
birth
give
full
protect
birth
serum
prolong
specif
yte
mutat
fc
tail
therebi
increas
affin
fcrn
receptor
keep
serum
antibodi
level
high
enough
give
protect
whole
rsv
season
confirm
phase
studi
yte
mutat
result
astonish
modifi
antibodi
day
therefor
like
one
inject
rsv
season
suffici
confer
protect
wherea
four
inject
palivizumab
need
confer
protect
protect
rsv
diseas
earli
life
import
prevent
seriou
damag
lung
recurr
wheez
discuss
report
recent
potenc
serum
depend
mainli
presenc
prefus
igg
therefor
protect
infant
elderli
later
life
lower
respiratori
tract
diseas
caus
rsv
vaccin
prefer
increas
serum
level
rsv
f
antibodi
extens
effort
underway
develop
test
rsv
vaccin
howev
advanc
trial
induct
neutral
antibodi
use
endpoint
wherea
clear
antibodi
inferior
prefus
f
antibodi
like
recent
prefus
vaccin
develop
base
knowledg
epitop
recogn
assumpt
vaccin
abl
preferenti
elicit
highli
neutral
prefus
antibodi
mention
follow
paragraph
also
abl
develop
potent
broadli
react
antibodi
influenza
stem
region
group
influenza
virus
inform
gener
efficaci
influenza
viru
vaccin
similar
done
group
influenza
also
gener
broadli
reactiv
highli
neutral
antibodi
human
parechoviru
viru
picornaviridea
famili
hcmv
hcv
like
knowledg
epitop
recogn
antibodi
also
inform
vaccin
develop
emerg
highli
pathogen
avian
influenza
infect
human
sinc
renew
interest
influenza
infect
therapeut
prevent
especi
neutral
antibodi
influenza
hemagglutinin
ha
major
glycoprotein
cell
surfac
viru
ha
mediat
viral
bind
interact
sialic
acid
glycoprotein
glycolipid
host
cell
therefor
antibodi
block
bind
site
prevent
viral
infect
neutral
antibodi
almost
alway
direct
ha
protein
influenza
virus
rapidli
mutat
side
known
antigen
drift
prevent
immun
viru
eighteen
subtyp
ha
identifi
cluster
two
group
base
sequenc
homolog
group
compris
group
compris
note
recent
identifi
bat
bind
sialic
acid
review
isol
broadli
neutral
antibodi
mice
show
influenza
neutral
antibodi
also
target
ha
epitop
conserv
differ
influenza
subtyp
recent
broad
neutral
antibodi
also
found
human
vaccin
influenza
viru
vaccin
search
human
neutral
antibodi
result
isol
antibodi
neutral
group
influenza
virus
although
antibodi
direct
ha
prevent
viral
infect
block
sialic
acid
bind
site
locat
top
ha
molecul
inhibit
conform
chang
need
fusion
viral
endosom
membran
mediat
bind
antibodi
conserv
hydrophob
pocket
stem
domain
ha
human
antibodi
employ
heavi
chain
germlin
gene
bind
sole
via
heavi
chain
light
chain
involv
subsequ
studi
identifi
critic
amino
acid
involv
interact
show
larg
proport
residu
germlin
encod
minim
contribut
mutat
residu
antibodi
protect
group
influenza
infect
set
isol
group
neutral
antibodi
first
enrich
b
cell
incub
transduc
polyclon
b
cell
pool
influenza
vaccin
donor
fluoresc
label
b
cell
bind
label
protein
isol
cultur
antibodi
contain
cultur
supernat
test
potenti
ha
procedur
let
identif
group
antibodi
renam
first
human
broadli
react
group
antibodi
identifi
antibodi
bind
similar
site
ha
stem
region
close
proxim
viral
membran
membran
proxim
conserv
epitop
describ
group
antibodi
broadli
neutral
group
antibodi
inhibit
viral
infect
prohibit
host
receptor
bind
block
conform
chang
ha
protein
need
viral
membran
fusion
inhibit
ha
process
independ
subsequ
studi
identifi
sever
broadli
neutral
group
antibodi
data
shown
potent
antibodi
show
neutral
capac
group
influenza
subtyp
test
bind
differ
epitop
stem
region
react
escap
mutant
highli
pathogen
influenza
viru
antibodi
antibodi
report
neutral
group
group
influenza
virus
bind
stem
region
ha
molecul
protect
mice
lethal
influenza
infect
except
group
antibodi
found
use
screen
system
util
life
b
cell
screen
nativ
pair
light
heavi
chain
antibodi
agreement
light
chain
antibodi
larg
contribut
target
bind
contrast
found
use
phage
display
target
bind
mediat
sole
via
heavi
chain
interact
hallmark
gc
reaction
occurr
somat
hypermut
variabl
domain
ig
locu
b
cell
b
cell
clone
increas
select
gener
effect
antibodi
respons
aid
encod
aicda
one
key
enzym
regul
somat
hypermut
express
gc
b
cell
employ
activ
aid
one
select
b
cell
mutat
immunoglobulin
produc
use
cell
line
ramo
b
cell
gener
recogn
sever
differ
antigen
even
though
b
cell
express
singl
rearrang
ig
gene
use
mammalian
cell
display
affin
matur
mimick
vitro
antibodi
aid
cell
line
follow
select
clone
increas
affin
improv
biophys
properti
could
identifi
line
phenotyp
aicda
transcript
express
b
cell
similar
quantiti
gc
b
cell
sequenc
analysi
transduc
b
cell
reveal
mutat
present
ig
locu
mainli
local
cdr
framework
indic
occurr
mutat
random
ig
variabl
mutat
rate
transduc
b
cell
mutat
per
base
pair
per
cell
divis
lower
end
estim
mutat
rate
vivo
ongo
somat
hypermut
lead
loss
specif
whole
pool
mutat
b
cell
form
small
part
total
popul
cultur
b
cell
retriev
small
subset
mutat
b
cell
within
pool
stain
cell
label
antigen
isol
cell
either
low
high
bind
avid
flow
cytometri
fig
way
isol
subclon
produc
antibodi
five
higher
affin
parent
antibodi
document
aid
express
control
basic
transcript
factor
activ
transcript
factor
inhibit
bind
form
inact
complex
consequ
overexpress
factor
inhibitor
dna
strongli
reduc
aicda
transcript
therebi
provid
method
prevent
mutat
vitro
affin
matur
transduc
b
cell
done
correl
bcr
express
level
pool
antigen
bind
capac
specif
select
b
cell
show
bind
pattern
deviat
median
use
strategi
could
increas
affin
one
b
cell
clone
least
sevenfold
nm
nm
addit
mutant
inform
residu
involv
antigen
bind
someth
determin
sequenc
analysi
alon
abil
optim
antibodi
perform
without
need
extens
sequenc
analysi
molecular
clone
one
uniqu
properti
antibodi
discoveri
platform
due
toler
nativ
human
protein
human
repertoir
may
harbor
desir
antibodi
self
specif
therefor
identifi
antibodi
human
protein
sometim
desir
immun
anim
obtain
antibodi
recent
monoclon
antibodi
almost
exclus
deriv
immun
mice
rat
explor
immort
introduct
could
also
appli
speci
immort
could
achiev
primat
mous
llama
rabbit
b
cell
tabl
particularli
retrovir
transduct
rabbit
b
cell
effici
tabl
fig
immort
rabbit
cell
grow
rapidli
averag
doubl
time
h
compar
h
human
cell
tabl
fig
allow
analysi
complet
repertoir
within
short
time
period
similar
transduc
human
b
cell
rabbit
b
cell
also
secret
immunoglobulin
express
bcr
cell
surfac
allow
sort
function
screen
secret
antibodi
rabbit
antibodi
high
interest
outperform
mous
antibodi
term
affin
divers
specif
peptid
modifi
protein
also
rabbit
antibodi
easili
select
mous
target
enabl
use
mani
human
diseas
model
final
identif
antibodi
react
human
protein
mous
counterpart
enabl
use
monoclon
preclin
clinic
studi
current
method
obtain
rabbit
monoclon
antibodi
includ
hybridoma
format
cell
fusion
rabbit
plasmacytoma
fusion
partner
develop
genet
modifi
rabbit
ii
phage
display
iii
vitro
differenti
cell
follow
sequenc
individu
b
cell
iv
analysi
polyclon
repertoir
comparison
serum
igg
databas
igg
variabl
gene
sequenc
construct
nextgen
sequenc
matur
b
cell
although
method
well
suit
identifi
antibodi
aris
high
frequenc
identifi
rare
antibodi
may
prove
costli
requir
extens
sequenc
recombin
express
effort
hybridoma
format
low
fusion
effici
instabl
clone
challeng
identif
rare
cell
indic
previou
paragraph
identif
rare
b
cell
produc
except
antibodi
instanc
desir
problem
use
rabbit
b
cell
assess
rabbit
b
cell
immort
use
platform
obtain
rabbit
monoclon
antibodi
immun
rabbit
human
influenza
vaccin
influvac
contain
influenza
b
alreadi
two
immun
transduc
b
cell
could
detect
high
frequenc
fig
show
human
cell
secret
antibodi
cell
surfac
express
bcr
could
use
identifi
specif
clone
seed
cell
parallel
singl
b
cell
bind
fluoresc
label
influenza
b
fig
subsequ
cultur
supernat
analyz
antibodi
bind
differ
compon
influenza
vaccin
elisa
supernat
unbias
contain
antibodi
direct
three
compon
vaccin
complet
vaccin
rabbit
fig
analysi
antibodi
produc
cell
show
major
antibodi
direct
compon
vaccin
use
sort
fig
thu
sort
allow
focus
popul
interest
clone
subsequ
test
bind
cell
investig
rabbit
immun
result
develop
rare
clone
inde
could
identifi
one
clone
show
correspond
frequenc
per
due
fast
doubl
time
immort
rabbit
b
cell
igg
b
cell
clone
obtain
within
week
blood
draw
expect
rabbit
antibodi
affin
individu
antibodi
extrem
high
pm
fact
anim
sacrif
allow
sequenti
sampl
take
analysi
similar
experi
aim
obtain
monoclon
antibodi
obtain
antibodi
recogn
flag
tag
peptid
estrogen
receptor
ngml
elisa
data
shown
summar
data
conclud
immort
rabbit
b
cell
offer
power
platform
quickli
obtain
rabbit
monoclon
antibodi
well
establish
activ
b
cell
express
high
amount
class
ii
major
histocompat
complex
mhc
protein
present
antigen
cell
antigen
taken
b
cell
via
bcr
process
peptid
deriv
antigen
present
cell
thu
physiolog
condit
antigen
b
cell
bcr
taken
process
present
cell
human
b
cell
expand
shown
present
antigen
peptid
b
cell
abl
present
nativ
antigen
cell
also
demonstr
b
cell
use
influenza
b
cell
clone
capabl
bind
intern
intact
show
nativ
control
protein
present
autolog
cell
clone
data
shown
expect
b
cell
present
variou
antigen
peptid
effici
autolog
cell
independ
bcr
specif
featur
success
appli
discov
neoantigen
deriv
highli
malign
melanoma
cell
recogn
cell
patient
research
first
determin
spectrum
mutat
protein
melanoma
exom
sequenc
made
librari
encompass
peptid
contain
mutat
screen
pool
peptid
capac
stimul
product
autolog
cell
cell
use
b
cell
establish
patient
importantli
immort
b
cell
activ
autolog
cell
absenc
neoantigen
contrast
b
cell
deriv
patient
b
cell
stimul
ebv
cell
mask
respons
neoantigen
show
import
b
cell
strategi
neoantigen
could
also
found
screen
use
dendrit
cell
dc
dc
expand
vitro
contrast
b
cell
limit
use
screen
describ
activ
b
cell
immort
simpl
genet
modif
nearli
complet
repertoir
captur
use
highli
effici
transduct
retrovir
construct
harbor
immort
b
cell
stabl
readili
clone
frozen
thaw
without
loss
capac
b
cell
phenotyp
secret
antibodi
supernat
express
bcr
surfac
make
excel
sourc
discoveri
monoclon
antibodi
librari
encompass
hundr
thousand
b
cell
establish
individu
produc
except
antibodi
facilit
rapid
antibodi
discoveri
allow
investig
search
rare
b
cell
make
uniqu
antibodi
discuss
exampl
broadli
react
highli
neutral
monoclon
antibodi
pathogen
virus
isol
select
individu
method
also
easili
appli
probe
repertoir
cancer
patient
respond
favor
immunotherapi
antibodi
recogn
tumor
antigen
alreadi
abl
identifi
antibodi
b
cell
cancer
patient
recogn
new
unexpect
target
cell
surfac
tumor
cell
futur
work
area
provid
us
better
understand
contribut
b
cell
immun
respons
malign
cell
also
allow
discoveri
novel
therapeut
antibodi
applic
method
speci
human
begin
explor
effici
gener
rabbit
monoclon
antibodi
offer
us
possibl
tap
except
properti
antibodi
also
possibl
make
monoclon
antibodi
primat
allow
analysi
repertoir
virus
like
human
immunodefici
viru
pathogen
human
primat
work
make
clear
express
suffici
chang
circul
b
cell
gc
b
cell
offer
ampl
opportun
studi
develop
function
cell
gc
one
exampl
concern
function
aid
b
cell
surprisingli
shm
observ
cell
csr
indic
yet
identifi
signal
requir
csr
asid
scientif
question
aid
express
b
cell
rais
could
use
featur
gener
subclon
b
cell
secret
antibodi
either
higher
lower
affin
antibodi
produc
parent
clone
therebi
offer
method
affin
matur
antibodi
without
need
extens
molecular
engin
final
b
cell
excel
cell
effici
present
peptid
intact
protein
process
bind
bcr
b
cell
clone
featur
allow
mechanist
studi
interact
b
cell
cell
human
speci
importantli
cultur
b
cell
establish
cancer
patient
provid
conveni
sourc
apc
discov
neoantigen
